Regulatory Crackdown Reshapes the Path for Hims & Hers

FDA warning letters and a Novo Nordisk lawsuit pressure Hims & Hers' compounded weight-loss drug model, prompting a strategic pivot to international growth.

The U.S. Food and Drug Administration (FDA) is intensifying scrutiny on the telehealth sector, creating significant headwinds for key industry players. On March 4, 2026, the regulatory body issued warning letters to 30 companies, including partners of the digital health platform Hims & Hers. The core allegation involves the improper marketing of compounded weight-loss medications. This action directly challenges a previously successful business model centered on offering affordable alternatives to popular GLP-1 agonist drugs.

Legal and Supply Chain Pressures Mount

The regulatory pressure coincides with escalating legal challenges. In February 2026, pharmaceutical giant Novo Nordisk filed a patent infringement lawsuit against Hims & Hers concerning compounded semaglutid. This legal move prompted the company to withdraw its recently launched tablet version of the blockbuster drug Wegovy from the market.

Adding to the uncertainty, a key manufacturing partner executed a notable reversal. On March 3, 2026, Strive Pharmacy confirmed it would not reintroduce the compounded Wegovy pill, contradicting prior communications. This decision signals a substantial barrier to the previous pathway for low-cost weight management pharmaceuticals.

Furthermore, the foundational legal premise for this segment is eroding. Hims & Hers had leveraged officially declared drug shortages for diabetes and obesity treatments to offer its own versions. However, the FDA has since declared the supply gaps for tirzepatid and semaglutid resolved, removing the legal justification for the mass compounding of these personalized medications.

Financial Performance and Strategic Pivot

The business transition is beginning to impact financial metrics. In the fourth quarter of 2025, the company's gross margin declined to 71.9 percent. Management has already cautioned investors about potential near-term revenue pressures due to shifting supply cycles within its weight-loss segment.

Despite these domestic regulatory challenges, the company's overall growth narrative remains strong. For the full year 2025, Hims & Hers reported a 59 percent surge in revenue, reaching $2.35 billion. Net profit stood at $128.4 million, while adjusted EBITDA climbed to $318 million. Its subscriber base also expanded, surpassing the 2.5 million member milestone.

International Expansion as a Counterbalance

In response to a tightening U.S. regulatory environment, the firm is aggressively pursuing international growth to diversify its reliance on its home market. A central component of this strategy is the planned acquisition of the global health platform Eucalyptus for up to $1.15 billion. Eucalyptus operates in Australia, Japan, Germany, and the United Kingdom. The transaction, expected to close by mid-2026, involves an upfront payment of approximately $240 million, with the remainder structured in installments through early 2029.

The company is also bolstering its presence in Canada. Following the acquisition of the digital weight-loss platform Livewell, Hims & Hers appointed Austin Kouri to lead its Canadian operations. International revenue has skyrocketed, posting growth of roughly 400 percent. The stated corporate objective is to generate over $1 billion in annual revenue from outside the United States within a three-year timeframe.

The critical question for investors is whether this international offensive can gain traction swiftly enough to offset mounting pressures in the core U.S. market. Forthcoming quarterly results will reveal the true extent of the impact on the weight-loss medication business and determine if the global diversification strategy will deliver its intended results.